214O - Multiplexed proteomics biomarkers for malignant pleural mesothelioma detection in blood

Date 13 April 2018
Event ELCC 2018 European Lung Cancer Congress
Session New approaches in rare thoracic tumors
Topics Mesothelioma
Thoracic Malignancies
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Ferdinando Cerciello
Citation Journal of Thoracic Oncology (2018) 13 (supp_4): S1-S139.
Authors F.W.F. Cerciello1, M. Choi2, S.L. Sinicropi-Yao1, E. Felley-Bosco3, R.A. Stahel4, B. Robinson5, J. Creaney5, H.I. Pass6, O. Vitek2, D.P. Carbone1
  • 1James Thoracic Center, James Cancer Center, The Ohio State University Medical Center, 43210 - Columbus/US
  • 2College Of Science, College Of Computer And Information Science, Northeastern University, Boston/US
  • 3Laboratory Of Molecular Oncology, Division Of Thoracic Surgery, University Hospital Zürich, 8044 - Zürich/CH
  • 4Department of Oncology, Center of Hematology and Oncology, Cancer Center Zürich, University Hospital Zürich, 8091 - Zürich/CH
  • 5National Centre For Asbestos Related Disease, University of Western Australia, School of Medicine and Pharmacology, Nedlands/AU
  • 6Langone Medical Center New York, New York University, New York/US


Blood biomarkers are not routinely applied for the diagnosis of malignant pleural mesothelioma (MPM). We investigated a multiplexed biomarkers signature composed of 6 glycopeptides for the diagnosis of MPM in blood using mass spectrometry based targeted proteomics.